ACE-031

Overview

ACE-031, also known as ramatercept, is an experimental biologic that was developed as a potential treatment for muscle-wasting conditions, most notably Duchenne muscular dystrophy. It is built as a soluble form of the ActRIIB receptor, designed to act as a decoy that intercepts signals which normally limit muscle growth. It is essential to state clearly that ACE-031 is not an approved drug, and its clinical development was halted for safety reasons.

The scientific rationale was attractive: by blocking the body's natural brakes on muscle building, ACE-031 aimed to increase muscle mass and strength in patients whose muscles are progressively deteriorating. For a devastating condition like Duchenne, the prospect of preserving or enhancing muscle drew considerable interest from researchers and families alike.

However, the clinical trials in Duchenne were stopped because of safety concerns, specifically vascular side effects including nosebleeds and the appearance of small dilated blood vessels in the skin. These signals raised enough worry to halt the program. ACE-031 is additionally banned by the World Anti-Doping Agency (WADA) because of its muscle-building potential, underscoring that it is both unapproved and prohibited in sport.

How it works

ACE-031 works by intercepting myostatin and related signaling molecules before they can reach their target receptor. Myostatin is a natural protein that acts as a negative regulator of muscle growth, essentially telling muscles to stop building. The ActRIIB receptor on muscle cells is one of the docking sites through which myostatin and similar factors deliver this restraining signal.

ACE-031 is engineered as a soluble decoy receptor: it contains the part of ActRIIB that binds these signaling molecules, but it floats freely in the circulation rather than sitting on a cell. By acting as a trap, it soaks up myostatin and related ligands, preventing them from engaging the real receptors on muscle. With the growth-limiting signal blocked, muscles are freed to grow larger and stronger.

The complication is that ActRIIB binds more than just myostatin. Several related signaling molecules use the same receptor, and some of these have roles in tissues beyond muscle, including the regulation of blood vessels. This lack of specificity is the likely explanation for the vascular side effects observed in trials, illustrating how a decoy that casts a wide net can disrupt processes well outside its intended target.

Research & evidence

ACE-031 was evaluated in clinical trials for Duchenne muscular dystrophy, reflecting genuine hope that a myostatin-blocking strategy could benefit patients with progressive muscle loss. Early interest centered on its potential to increase muscle mass where existing options were limited. The investigational program represented a serious attempt to translate myostatin biology into a therapy.

The decisive finding, however, was on the safety side. The trials were halted after participants experienced vascular side effects, including nosebleeds and telangiectasias, the small dilated blood vessels visible in the skin. These effects pointed to off-target activity affecting blood vessels, and they were significant enough that continuing the program was judged unacceptable. The halt is the central fact of the ACE-031 record.

As a result, ACE-031 never advanced to approval, and its development effectively stalled. The honest framing is that it serves as an instructive example of a promising mechanism undermined by safety problems rooted in receptor non-specificity. The experience also informed subsequent efforts to design more selective myostatin-pathway agents. ACE-031 itself remains an unapproved, discontinued experimental biologic rather than a viable treatment.

Safety & legal status

ACE-031 is not approved by the FDA or any other regulator, and its clinical development was discontinued. Its trials were stopped specifically because of vascular safety concerns, including nosebleeds and telangiectasias, which are believed to stem from the compound's effects on signaling pathways involved in blood vessels. These are not speculative worries but documented findings that ended the program, and they make any unsupervised use particularly hazardous.

In addition to lacking approval, ACE-031 is prohibited by the World Anti-Doping Agency (WADA). As a myostatin-pathway inhibitor with muscle-building potential, it falls within the categories of substances banned in competitive sport, and its use by athletes would constitute a doping violation. Any product marketed as ACE-031 outside legitimate research would be unregulated, with no assurance of identity, purity, or safety.

This guide provides no dosing or usage guidance, consistent with the fact that ACE-031 is a discontinued experimental biologic with a known safety signal. Individuals affected by muscle-wasting conditions should pursue approved, medically supervised therapies and clinical trial opportunities rather than seeking access to halted compounds through unofficial channels.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: a randomized, placebo-controlled trial. Muscle Nerve. 2017. Peer-reviewed study
2. Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013. Peer-reviewed study
3. Reichel C, Filip T, Gmeiner G, et al. Gel Electrophoretic Detection of Black Market ACE-031. Drug Test Anal. 2025. Peer-reviewed study
4. Cadena SM, Bogdanovich S, Khurana TS, et al. ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus). bioRxiv. 2025. Peer-reviewed study
5. Cadena SM, Bogdanovich S, Khurana TS, et al. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PLoS One. 2026. Peer-reviewed study